Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $29,267 | 7 | 96.6% |
| Travel and Lodging | $592.31 | 3 | 2.0% |
| Food and Beverage | $443.34 | 9 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $15,653 | 5 | $0 (2018) |
| Merck Sharp & Dohme LLC | $7,604 | 9 | $0 (2024) |
| AstraZeneca AB | $5,175 | 3 | $0 (2023) |
| SANOFI US SERVICES INC. | $1,764 | 1 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $105.77 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,479 | 6 | Merck Sharp & Dohme LLC ($7,479) |
| 2023 | $1,575 | 1 | AstraZeneca AB ($1,575) |
| 2022 | $3,600 | 2 | AstraZeneca AB ($3,600) |
| 2018 | $15,642 | 4 | Teva Pharmaceuticals USA, Inc. ($15,642) |
| 2017 | $2,007 | 6 | SANOFI US SERVICES INC. ($1,764) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,115.00 | General |
| 10/14/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $48.49 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.04 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $26.94 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,092.50 | General |
| 01/24/2023 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| 03/29/2022 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 03/29/2022 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 07/12/2018 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $15,120.00 | General |
| 07/11/2018 | Teva Pharmaceuticals USA, Inc. | — | Travel and Lodging | In-kind items and services | $408.24 | General |
| 07/11/2018 | Teva Pharmaceuticals USA, Inc. | — | Food and Beverage | In-kind items and services | $79.27 | General |
| 07/11/2018 | Teva Pharmaceuticals USA, Inc. | — | Travel and Lodging | In-kind items and services | $34.07 | General |
| 09/12/2017 | Teva Pharmaceuticals USA, Inc. | CINQAIR (Drug) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: Respiratory | ||||||
| 07/18/2017 | SANOFI US SERVICES INC. | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | Cash or cash equivalent | $1,764.00 | General |
| 07/18/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $105.77 | General |
| 07/13/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 07/13/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 07/13/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $34.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 24 | $9,722 | $1,900 |
| 2022 | 3 | 41 | 75 | $44,926 | $9,619 |
| 2021 | 1 | 20 | 63 | $56,403 | $11,913 |
| 2020 | 4 | 87 | 179 | $114,188 | $24,893 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 15 | 24 | $9,722 | $1,900 | 19.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 16 | 32 | $27,520 | $5,909 | 21.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 28 | $11,396 | $2,443 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 15 | $6,010 | $1,266 | 21.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 20 | 63 | $56,403 | $11,913 | 21.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 32 | 95 | $84,173 | $18,486 | 22.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 53 | $22,025 | $4,776 | 21.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 19 | $5,537 | $1,185 | 21.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 11 | 12 | $2,453 | $445.61 | 18.2% |
About Dr. Bruce Levy, MD
Dr. Bruce Levy, MD is a Pulmonary Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043277353.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Levy, MD has received a total of $30,302 in payments from pharmaceutical and medical device companies, with $7,479 received in 2024. These payments were reported across 19 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($29,267).
As a Medicare-enrolled provider, Levy has provided services to 163 Medicare beneficiaries, totaling 341 services with total Medicare billing of $48,325. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Location Boston, MA
- Active Since 04/28/2006
- Last Updated 11/24/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1043277353
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $1,870
- CINQAIR (Drug) $11.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Boston
Bartolome Celli, Md, MD
Pulmonary Disease — Payments: $613,474
Adnan Majid, Md, MD
Pulmonary Disease — Payments: $424,602
Avrum Spira, M.d, M.D
Pulmonary Disease — Payments: $157,114
Dr. Tufik Assad, M.d, M.D
Pulmonary Disease — Payments: $151,341
Dr. Benjamin Medoff, Md, MD
Pulmonary Disease — Payments: $136,103
Kelsey Sack, Md/Phd, MD/PHD
Pulmonary Disease — Payments: $82,500